Cargando…

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary

OBJECTIVE: The objective of this study was to evaluate the antitumor effects of lurbinectedin as a single agent or in combination with existing anticancer agents for clear cell carcinoma (CCC) of the ovary, which is regarded as an aggressive, chemoresistant, histological subtype. METHODS: Using huma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Ryoko, Mabuchi, Seiji, Kawano, Mahiru, Sasano, Tomoyuki, Matsumoto, Yuri, Kuroda, Hiromasa, Kozasa, Katsumi, Hashimoto, Kae, Sawada, Kenjiro, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/ https://www.ncbi.nlm.nih.gov/pubmed/26986199 http://dx.doi.org/10.1371/journal.pone.0151050

Ejemplares similares

The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer
por: Kawano, Mahiru, et al.
Publicado: (2015)

Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer
por: Kuroda, Hiromasa, et al.
Publicado: (2018)

Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models
por: Kozasa, Katsumi, et al.
Publicado: (2019)

Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review
por: Kozasa, Katsumi, et al.
Publicado: (2017)

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
por: Calvo, E., et al.
Publicado: (2017)

Effect of Japanese Kampo Medicine Therapy for Menopausal Symptoms after Treatment of Gynecological Malignancy
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies
por: Mabuchi, Seiji, et al.
Publicado: (2020)

Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
por: Shimura, Kotaro, et al.
Publicado: (2021)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma
por: Yokoi, Eriko, et al.
Publicado: (2017)

Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors
por: Matsuo, Koji, et al.
Publicado: (2015)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
por: Mabuchi, Seiji, et al.
Publicado: (2016)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
por: Fudio, Salvador, et al.
Publicado: (2023)

Sensitivity to Anticancer Agents and Resistance Mechanisms in Clear Cell Carcinoma of the Ovary
por: Itamochi, Hiroaki, et al.
Publicado: (2002)

Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer
por: Komura, Naoko, et al.
Publicado: (2019)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
por: Mabuchi, Seiji, et al.
Publicado: (2011)

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
por: Kundu, Kiran, et al.
Publicado: (2021)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012)

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers
por: Mabuchi, Seiji, et al.
Publicado: (2021)

Kerosene: Contributing agent to xylene as a clearing agent in tissue processing
por: Shah, Amisha Ashokkumar, et al.
Publicado: (2017)

Clearing and Masking Agents in Pretargeting Strategies
por: Staudt, Markus, et al.
Publicado: (2023)

Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer
por: Sawada, Kenjiro, et al.
Publicado: (2012)

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma
por: Kinose, Yasuto, et al.
Publicado: (2015)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Alternative to xylene as a clearing agent in histopathology
por: Alwahaibi, Nasar, et al.
Publicado: (2018)

Efferocytosis and autoimmune disease
por: Kawano, Mahiru, et al.
Publicado: (2018)

Premetastatic niche and tumor-related leukocytosis: a close relationship that cannot be ignored in uterine cancer patients
por: Mabuchi, Seiji, et al.
Publicado: (2018)

Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer
por: Mabuchi, Seiji, et al.
Publicado: (2021)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
por: Povo-Retana, Adrián, et al.
Publicado: (2020)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Lurbinectedin improves macular edema in a case of central retinal vein occlusion()
por: Simona, Filippo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qas6ffpn78hv9d8feu2a7dd73s